

China imatinib mesylate market

[Finance](#), [Market](#)



The mortality of leukemia ranks sixth among tumors while its incidence and mortality ranks first among malignant tumors for teenagers.

The incidence of leukemia reaches two age peaks: 0-9 years old and above 60 years old. Imatinib mesylate was a tyrosine kinase inhibitor developed by Novartis. On May 10, 2001, Imatinib mesylate got FDA's express approval with the trade name of Glivec due to its groundbreaking anti-tumor mechanism. On Dec. 23, 2009, Imatinib mesylate gained its status as the first-line treatment for chronic myeloid leukemia under FDA's approval.

And now it has been approved for treatment of chronic myeloid leukemia in more than 80 countries around the world. View Full Report at: <http://www.Nonrepresentational.Biz/analysis/289058> After entering Chinese market on Mar. 17, 2002, Imatinib mesylate has developed fast with annual sales reaching CNY 532 million in 2014 and CAGR reaching up to 42% during the period of 2005-2014. Currently, Imatinib mesylate in the Chinese market is made by the following three companies: Novartis (Swiss), Sino-American Attaining Pharmaceutical Group Co. Ltd and Hanson Pharmaceutical, among which Novartis has the largest market share of over 98% with sales value reaching up to CNY 523 million in 2014. Imatinib mesylate has accurate curative effects on chronic myeloid leukemia despite its relatively high price. Chinese patients with low incomes were once sued for purchasing Imatinib mesylate smuggled from India whose price is only 10% or less of that in Chinese market. As China's economy develops, people's income and purchasing power increases.